We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Admits Biosimilar Neupogen Infringes Amgen’s Patents
Teva Pharmaceutical’s biosimilar of Amgen’s cancer treatment Neupogen has hit another snag as the world’s largest generic-drug maker agreed not to market its version until a month before the biologic’s patents expire in late 2013.